SIRT1 and malignant colon neoplasm: The bicyclic inhibitor also demonstrated on-target cellular activity, as demonstrated by increased acetylation of the Sirt1 substrate p53 in the HCT116 colon cancer cell line and decreased proliferation of a melanoma cell line that is susceptible to Sirt1/3 inhibition [192].